Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Boosting Business Acumen: Chicago Booth’s Executive Education Program in Finance Workshop for Non-Financial Leaders–Available in Hong Kong and Chicago
From Chicago Booth Executive Education
Via Business Wire
New Operation HOPE Research Finds That Financial Literacy Resources, Tools & Coaching Services Are Key Drivers of Optimism Despite Uncertain Economic Times
From Operation HOPE, Inc.
Via Business Wire
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
From Alexion
Via Business Wire
Tickers AZN
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
From MorphoSys AG
Via Business Wire
Tickers MOR
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
From Incyte and Syndax Pharmaceuticals
Via Business Wire
Tickers INCY SNDX
Morrow Sodali Acquires Australian Corporate Communication Consultancy, Domestique
From Morrow Sodali
Via Business Wire
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​
From Be Biopharma, Inc.
Via Business Wire
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
From Schrödinger
Via Business Wire
Tickers SDGR
NKLA DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA
From The Rosen Law Firm, P.A.
Via Business Wire
Tickers NKLA
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
Tickers GLYC
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
Teoayeah’s Christmas Gift List for All Kids (12/11-12/24)
From Teoayeah
Via Business Wire
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Belgian, Port Houston and Partners Sign Memorandum of Understanding on Energy Transition Cooperation
From Port Houston
Via Business Wire
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
From Pfizer Inc.
Via Business Wire
Tickers PFE
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting
From Orca Bio
Via Business Wire
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Tickers LPSN
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
From Scenic Biotech
Via Business Wire
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Port Houston Regular Commission Meeting
From Port Houston
Via Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
AYA Platform of Enjinstarter Granted Virtual Asset Service Provider Licence by Dubai’s Virtual Assets Regulatory Authority
From Enjinstarter
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.